A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma

NCT00272415 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: INO-1001
DRUG: temozolomide

Sponsor

Genentech, Inc.